Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental drug tested for painful skin blistering disease

NCT ID NCT02226146

Summary

This small, early-stage study tested an experimental drug called bertilimumab in 11 older adults newly diagnosed with moderate to severe bullous pemphigoid, a condition that causes large, itchy skin blisters. The main goals were to check the drug's safety and see if it could reduce blistering and itching while helping patients lower their steroid medication doses. Researchers measured skin symptoms, quality of life, and how well patients could taper off prednisone.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEMPHIGOID, BULLOUS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Research Site

    Iowa City, Iowa, United States

  • Research Site

    Buffalo, New York, United States

  • Research Site

    New York, New York, United States

  • Research Site

    Durham, North Carolina, United States

  • Research Site

    Cleveland, Ohio, 10900, United States

  • Research Site

    Salt Lake City, Utah, United States

  • Research Site

    Ramat Gan, 5262100, Israel

  • Research Site

    Tel Aviv, 64239, Israel

Conditions

Explore the condition pages connected to this study.